Related Experiment Video

Updated: Sep 22, 2025

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
07:01

Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models

Published on: May 10, 2022

1.6K

Biomimetic micelles to accurately regulate the inflammatory microenvironment for glomerulonephritis treatment

Huijuan Zhang1, Qingqing He2, Jingjing Wang2

  • 1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China; Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Henan Province, China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Zhengzhou, Henan Province, China.

Pharmacological Research
|May 21, 2022
PubMed

Insights

A novel nanomicelle therapy targets glomerulonephritis by reprogramming macrophages and killing mesangial cells. This dual-action approach shows promise in reducing kidney inflammation and proteinuria.

Area of Science:

  • Nephrology
  • Biomaterials Science
  • Nanomedicine

Background:

  • Glomerulonephritis is a primary cause of end-stage renal disease.
  • Mesangial cell proliferation and macrophage infiltration drive disease progression in a detrimental cycle.

Purpose of the Study:

  • To develop a novel biomimetic nanomicelle (MM/HA-DXM) for synergistic treatment of glomerulonephritis.
  • To leverage hyaluronic acid (HA) for macrophage modulation and dexamethasone (DXM) for mesangial cell targeting.

Main Methods:

  • Constructed macrophage membrane-camouflaged, pH-sensitive nanomicelles (MM/HA-DXM).
  • Utilized HA to convert M1 macrophages to anti-inflammatory M2 phenotype.
  • Employed DXM to inhibit mesangial cell proliferation.
  • Evaluated targeting and therapeutic efficacy in doxorubicin-induced glomerulonephritis models.

Main Results:

  • MM/HA-DXM exhibited enhanced homing to inflamed renal tissue (4.33-fold improvement).
  • Treatment significantly reduced proteinuria levels (2.33-fold decrease compared to control).
  • Demonstrated a synergistic therapeutic effect through dual-action anti-inflammatory strategy.

Conclusions:

  • The MM/HA-DXM nanomicelle system offers precise and effective treatment for glomerulonephritis.
  • This biomimetic approach successfully remodels the glomerular inflammatory microenvironment.
  • The strategy holds potential for improving outcomes in kidney disease patients.
Keywords:
Biomimetic nanomicellesCollaborative anti-inflammatory therapyGlomerulonephritisHomologous targetingPH-sensitive

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

555
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
243
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
281
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
57
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
30
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
206
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
630